CA3000815C - Anticorps anti-age et procedes d'utilisation correspondants - Google Patents

Anticorps anti-age et procedes d'utilisation correspondants Download PDF

Info

Publication number
CA3000815C
CA3000815C CA3000815A CA3000815A CA3000815C CA 3000815 C CA3000815 C CA 3000815C CA 3000815 A CA3000815 A CA 3000815A CA 3000815 A CA3000815 A CA 3000815A CA 3000815 C CA3000815 C CA 3000815C
Authority
CA
Canada
Prior art keywords
antibody
age
seq
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3000815A
Other languages
English (en)
Other versions
CA3000815A1 (fr
Inventor
Lewis S. Gruber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siwa Corp
Original Assignee
Siwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/974,561 external-priority patent/US10358502B2/en
Application filed by Siwa Corp filed Critical Siwa Corp
Publication of CA3000815A1 publication Critical patent/CA3000815A1/fr
Application granted granted Critical
Publication of CA3000815C publication Critical patent/CA3000815C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'invention concerne un anticorps anti-AGE, comprenant une protéine ou un peptide qui comprend au moins une séquence d'acides aminés présentant une identité de séquence d'au moins 90 %, de préférence une identité de séquence d'au moins 95 %, plus préférablement une identité de séquence d'au moins 98 %, par rapport à des séquences d'acides aminés spécifiques. L'anticorps anti-AGE se lie à une protéine ou à un peptide qui présente une modification carboxyméthyllysine. L'anticorps anti-AGE peut être utilisé pour tuer des cellules sénescentes, pour tuer des cellules partiellement fonctionnelles ou non fonctionnelles, pour traiter la sarcopénie, pour favoriser la régénération d'organes ou de tissus, pour favoriser des processus de régénération ou surmonter les effets de vieillissement, pour traiter l'athérosclérose, pour prévenir ou retarder l'apparition de la cataracte, pour prévenir ou retarder l'apparition d'une perte de tissu adipeux, pour augmenter la durée de vie en santé, pour prévenir ou retarder l'apparition de la lordo-cyphose, pour traiter l'inflammation ou les maladies auto-immunes, pour traiter des troubles neurodégénératifs ou pour traiter le cancer.
CA3000815A 2015-10-13 2016-05-27 Anticorps anti-age et procedes d'utilisation correspondants Active CA3000815C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562241007P 2015-10-13 2015-10-13
US62/241,007 2015-10-13
US14/974,561 2015-12-18
US14/974,561 US10358502B2 (en) 2014-12-18 2015-12-18 Product and method for treating sarcopenia
PCT/US2016/034880 WO2017065837A1 (fr) 2015-10-13 2016-05-27 Anticorps anti-age et procédés d'utilisation correspondants

Publications (2)

Publication Number Publication Date
CA3000815A1 CA3000815A1 (fr) 2017-04-20
CA3000815C true CA3000815C (fr) 2022-11-01

Family

ID=58518256

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3000815A Active CA3000815C (fr) 2015-10-13 2016-05-27 Anticorps anti-age et procedes d'utilisation correspondants

Country Status (12)

Country Link
EP (1) EP3362483A1 (fr)
JP (1) JP2018535953A (fr)
KR (1) KR20180056689A (fr)
CN (1) CN108431044A (fr)
AU (1) AU2016336959A1 (fr)
BR (1) BR112018007422A2 (fr)
CA (1) CA3000815C (fr)
IL (1) IL258397A (fr)
MA (1) MA42979A (fr)
MX (1) MX2018004545A (fr)
RU (1) RU2766209C2 (fr)
WO (1) WO2017065837A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120127543A (ko) 2008-05-23 2012-11-21 시와 코퍼레이션 재생을 촉진하는 방법, 조성물 및 장치
US9649376B2 (en) 2010-09-27 2017-05-16 Siwa Corporation Selective removal of age-modified cells for treatment of atherosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
RU2721568C2 (ru) 2014-09-19 2020-05-20 Сива Корпорейшн Анти-age антитела для лечения воспаления и аутоиммунных нарушений
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
CN109071675A (zh) * 2016-02-19 2018-12-21 Siwa有限公司 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物
CA3057829A1 (fr) 2016-04-15 2017-10-19 Siwa Corporation Anticorps anti-age pour le traitement de troubles neurodegeneratifs
EP3475306A1 (fr) 2016-06-23 2019-05-01 Siwa Corporation Vaccins pour l'utilisation dans le traitement de diverses maladies et troubles
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
EP3609923A1 (fr) 2017-04-13 2020-02-19 Siwa Corporation Anticorps monoclonal humanisé de produit final de glycation avancée
KR20200003067A (ko) * 2017-05-04 2020-01-08 시와 코퍼레이션 진단용 최종 당화 산물 항체
JP6994876B2 (ja) * 2017-09-05 2022-01-14 株式会社エッグ 計測器
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2019183282A1 (fr) * 2018-03-21 2019-09-26 Mayo Foundation For Medical Education And Research Agents sénolytiques pour le traitement de tauopathies
EP3826670A1 (fr) * 2018-07-23 2021-06-02 Siwa Corporation Méthodes et compositions destinées à traiter les effets chroniques de l'exposition aux rayonnements et aux substances chimiques
JP2021534144A (ja) * 2018-08-23 2021-12-09 シワ コーポレーション Ａｇｅ修飾細胞を除去するための、抗カルボキシメチルリシン抗体及び超音波
CN115996954A (zh) * 2020-05-01 2023-04-21 Siwa有限公司 治疗感染的方法
CN117642431B (zh) * 2021-07-13 2025-07-15 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
CN114957470B (zh) * 2021-11-12 2023-01-17 深圳市人民医院 靶向rage的纳米抗体及其应用
WO2023177390A1 (fr) * 2022-03-14 2023-09-21 Siwa Corporation Anticorps monoclonal humanisé de produit final de glycation avancée pour le traitement du cancer du pancréas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
RU2270029C2 (ru) * 1999-06-25 2006-02-20 Джинентех, Инк. ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ ОБЛАДАЕТ СПОСОБНОСТЬЮ СВЯЗЫВАТЬ ErbB2 И БЛОКИРОВАТЬ АКТИВАЦИЮ ЛИГАНДОМ РЕЦЕПТОРА ErbB (ВАРИАНТЫ) И КОМПОЗИЦИЯ ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ РАКА, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО
JP4012722B2 (ja) * 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
WO2007098186A2 (fr) 2006-02-22 2007-08-30 Novavax, Inc. Compositions d'adjuvant et de vaccin
KR20120127543A (ko) 2008-05-23 2012-11-21 시와 코퍼레이션 재생을 촉진하는 방법, 조성물 및 장치

Also Published As

Publication number Publication date
CA3000815A1 (fr) 2017-04-20
RU2018110885A (ru) 2019-11-19
RU2018110885A3 (fr) 2020-01-30
MX2018004545A (es) 2018-08-01
EP3362483A1 (fr) 2018-08-22
KR20180056689A (ko) 2018-05-29
RU2766209C2 (ru) 2022-02-09
MA42979A (fr) 2021-05-26
BR112018007422A2 (pt) 2018-10-30
CN108431044A (zh) 2018-08-21
JP2018535953A (ja) 2018-12-06
AU2016336959A1 (en) 2018-04-12
WO2017065837A1 (fr) 2017-04-20
IL258397A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
CA3000815C (fr) Anticorps anti-age et procedes d'utilisation correspondants
US20250250331A1 (en) Anti-age antibodies for treating neurodegenerative disorders
US11873345B2 (en) Product and method for treating sarcopenia
US10889634B2 (en) Anti-age antibodies and methods of use thereof
EP3677598B1 (fr) Procédé et composition pour traiter le cancer, tuer des cellules du cancer métastatique et prévenir des métastases cancéreuses à l'aide d'anticorps pour produits finaux de glycation avancée (age)
US10919957B2 (en) Humanized monoclonal advanced glycation end-product antibody
WO2023177390A1 (fr) Anticorps monoclonal humanisé de produit final de glycation avancée pour le traitement du cancer du pancréas
AU2018251183A1 (en) Humanized monoclonal advanced glycation end-product antibody
HK40081546A (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
HK40029952A (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
HK40029952B (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
HK1256931B (en) Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210427

EEER Examination request

Effective date: 20210427

EEER Examination request

Effective date: 20210427

EEER Examination request

Effective date: 20210427

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - SMALL

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241018

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241018